ABSTRACT The mitochondrial pyruvate carrier (MPC) plays a role in numerous diseases including neurodegeneration, metabolically dependent cancers, and the development of insulin resistance. Several previous studies in genetic mouse models or with existing inhibitors suggest that inhibition of the MPC could be used as a viable therapeutic strategy in these diseases. However, the MPC’s structure is unknown, making it difficult to screen for and develop therapeutically viable inhibitors. Currently known MPC inhibitors…